These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000134-37 Trial to Reduce Cardiovascular Events with Aranesp Therapy 2009-07-23 due-trials
Reported results 2004-000138-35 A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis 2008-10-14 due-trials
Reported results 2004-000172-13 AN OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF LONG-TERM DOSING OF AMG 531 IN THROMBOCYTOPENIC SUBJECTS WITH IMMUNE (IDIOPATHIC) THROMBOCITOPENIC PURPURA Studio in aperto per valutare la... 2010-01-26 due-trials
Reported results 2004-000173-65 A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy 2006-12-27 due-trials
Reported results 2004-000174-31 A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splene... 2006-11-01 due-trials
Reported results 2004-000509-24 A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy 2006-06-15 due-trials
Completed, but no date, and reported results 2004-000511-25 A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates bad-data
Reported results 2004-000512-17 A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer 2008-05-14 due-trials
Exempt 2004-000645-37 A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-myeloid Malignancies... not-yet-due
Reported results 2004-001154-86 A Multicenter, Double-blind, Placebo-controlled Roll-over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer 2007-01-17 due-trials
Reported results 2004-001417-33 A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy 2006-08-01 due-trials
Reported results 2004-002016-28 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction... 2016-07-11 due-trials
Reported results 2004-002165-20 An Open Label Study of AMG 706 in Subjects with Advanced Gastrointestinal Stromal Tumors (GISTs) who Developed Progressive Disease or Relapsed While on Imatinib Mesylate 2007-03-07 due-trials
Reported results 2004-002310-10 Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism 2005-11-10 due-trials
Reported results 2004-004178-10 A Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the... 2006-08-28 due-trials
Reported results 2004-004499-35 A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects with Chronic Kidney Disease Receiving Haemodialysis 2006-10-05 due-trials
Ongoing 2004-004558-18 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis not-yet-due
Reported results 2004-005007-14 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With St... 2014-03-31 due-trials
Exempt, with results 2004-005252-14 Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI): Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronar... 2006-11-28 not-yet-due
Reported results 2005-000213-35 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction... 2017-07-11 due-trials
Reported results 2005-001618-42 A Phase 2 Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer 2007-03-13 due-trials
Reported results 2005-003558-83 A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis. 2008-02-06 due-trials
Reported results 2005-004323-18 An Open Label Study Treatment Extension Study of AMG 706 Studio in aperto di estensione del trattamento con AMG706 2012-07-16 due-trials
Reported results 2005-004642-14 Estudio abierto, de un solo grupo, de palifermin para la reducción de la mucositis en sujetos con linfoma no Hodgkin (LNH) o mieloma múltiple (MM) sometidos a quimioterapia a altas dosis y trasplante ... 2007-04-26 due-trials
Reported results 2005-004643-53 Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease 2011-05-13 due-trials
Reported results 2005-004676-20 "A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Co... 2010-09-13 due-trials
Reported results 2005-005081-37 A Randomized, Double-Blind Study to Compare the Efficacy of Treatment with Denosumab versus Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density 2007-12-07 due-trials
Completed, but no date, and reported results Terminated 2005-005271-15 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Densi... bad-data
Reported results 2005-005275-15 A Randomized, Double- Blind, Placebo- Controlled, Multi- Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects with Non- Metastatic Breast Cancer Receiving Aromatase Inhibito... 2022-07-26 due-trials
Reported results 2005-005278-59 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptom... 2012-10-11 due-trials
Reported results 2005-005484-28 A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab 2011-11-14 due-trials
Reported results 2005-005485-37 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-refractory Prostate Cancer 2014-04-09 due-trials
Reported results 2006-000074-79 A Multicenter, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis 2007-06-05 due-trials
Reported results 2006-000091-32 A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women with H... 2012-05-30 due-trials
Reported results 2006-000144-92 An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) 2008-06-10 due-trials
Reported results 2006-000170-70 A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin... 2013-01-24 due-trials
Reported results 2006-000339-93 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer 2012-04-04 due-trials
Reported results 2006-000341-19 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer Studio M... 2012-02-27 due-trials
Reported results 2006-000848-65 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa 63720; in the Treatment of Bone Metastases in Subjects with Advanced Cancer Excluding Breast and Pro... 2011-08-24 due-trials
Reported results 2006-000849-19 A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density 2008-03-18 due-trials
Reported results 2006-002075-40 EVOLVE Evaluation of Cinacalcet HCI Therapy to lower CardioVascular events. 2012-03-21 due-trials
Reported results 2006-002662-19 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Studio randomizzato... 2009-05-15 due-trials
Reported results 2006-003173-27 A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis 2012-04-10 due-trials
Reported results 2006-003698-29 A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis 2008-06-11 due-trials
Reported results 2006-003699-36 A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subje... 2008-12-02 due-trials
Reported results 2006-003700-18 A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopath... 2009-11-05 due-trials
Reported results 2006-003709-15 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj... 2011-11-22 due-trials
Reported results 2006-003784-32 A Phase 3, Multicenter, Randomized, Placebo Controlled, Double Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non small Cell Lung Cancer 2012-12-14 due-trials
Completed, but no date, and reported results 2006-003785-33 A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma bad-data
Reported results 2006-003786-13 A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck 2012-03-12 due-trials
Reported results 2006-006520-19 An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of positi... 2014-11-26 due-trials
Exempt, with results 2006-006658-89 A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer 2011-03-23 not-yet-due
Reported results 2006-006739-36 A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancer 2012-08-02 due-trials
Reported results 2006-006964-48 An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone 2010-11-16 due-trials
Reported results 2007-000147-98 A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastat... 2014-06-10 due-trials
Reported results 2007-000570-22 A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer 2008-01-10 due-trials
Reported results 2007-000573-29 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism 2013-06-17 due-trials
Reported results 2007-000638-37 An Open Label Study of AMG 531 in Severely Refractory Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2011-01-05 due-trials
Reported results 2007-001041-17 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis 2015-07-29 due-trials
Reported results 2007-001438-15 A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck 2011-12-16 due-trials
Reported results 2007-001439-74 A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck 2011-04-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001516-24 An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS) 2012-06-12 bad-data
Reported results 2007-003384-51 A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG386 plus Paclitaxel as First-Line Therapy in Subjects with Her2-Negative, Metastat... 2014-05-19 due-trials
Reported results 2007-003569-42 Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 1/2 para Determinar la Seguridad y la Eficacia de AMG 531 en Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica Inmu... 2009-03-03 due-trials
Reported results 2007-003573-50 A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in Sub... 2012-06-06 due-trials
Reported results 2007-004722-25 A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer 2010-11-04 due-trials
Reported results 2007-005722-79 A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and ... 2014-03-06 due-trials
Reported results 2007-005792-34 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 μg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced ... 2018-06-05 due-trials
Reported results 2007-006050-25 An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metas... 2011-09-23 due-trials
Reported results 2007-007258-75 A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome... 2015-12-10 due-trials
Reported results 2008-001605-42 A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Effica... 2013-06-19 due-trials
Trial is partly outside EEC, and reported results 2008-001606-16 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone 2018-05-17 bad-data
Completed, but no date, and reported results 2008-001721-34 A Phase 2, Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Darbepoetin alfa for the Treatment of Anemia in Paediatric Subjects with Solid Tumours Receiving Cyclic Chemotherapy bad-data
Reported results 2008-001751-21 A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer 2013-10-31 due-trials
Reported results 2008-003258-14 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of AMG 386 in Combination with FOLFIRI in Subjects with Previously Treated Metastatic Colorectal Carcinoma 2012-05-16 due-trials
Reported results 2008-003292-42 A Phase 1b/ 2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer 2013-02-28 due-trials
Trial is partly outside EEC, and reported results 2008-003418-88 A Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Rec... 2014-03-03 bad-data
Reported results 2008-004281-71 A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously U... 2016-07-16 due-trials
Reported results 2008-004347-10 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Imm... 2014-01-09 due-trials
Exempt, with results 2008-004355-30 A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer 2012-04-30 not-yet-due
Reported results 2008-004438-25 A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer 2019-12-09 due-trials
Reported results 2008-004558-34 Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Ini... 2012-12-21 due-trials
Reported results 2008-004752-77 A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irino... 2022-07-22 due-trials
Exempt, with results 2008-005074-12 A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Estud... 2011-08-10 not-yet-due
Reported results 2008-005140-16 Inhibición de la Delta-PROTEína cinasa C para la reducCCIÓN del tamaño del infarto en Infarto Agudo de Miocardio (PROTECCIÓN IAM) Inhibition of Delta-PROTEin kinase C for the reducTION of infarct size... 2011-06-17 due-trials
Reported results 2008-005301-19 A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-... 2012-06-04 due-trials
Reported results 2008-005991-28 A Randomized, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women with Low Bone Mineral Density 2016-02-03 due-trials
Reported results 2008-006154-17 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic P... 2012-05-13 due-trials
Reported results 2008-006210-14 Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic ... 2019-06-24 due-trials
Reported results 2008-006212-38 Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma. 2015-06-21 due-trials
Reported results 2008-008392-34 A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation wi... 2013-07-11 due-trials
Reported results 2009-009374-27 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma 2012-04-28 due-trials
Reported results 2009-009756-21 A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonate... 2013-08-21 due-trials
Reported results 2009-010205-37 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab versus Placebo in Males with Low Bone Mineral Density 2012-05-23 due-trials
Reported results 2009-010587-42 A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy. 2012-01-17 due-trials
Reported results 2009-010715-32 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer 2017-07-22 due-trials
Reported results 2009-010726-19 A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates. 2011-11-09 due-trials
Reported results 2009-011299-32 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence 2018-03-26 due-trials
Reported results 2009-011899-30 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizuma... 2015-01-02 due-trials
Reported results 2009-012076-26 A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation ... 2016-05-12 due-trials
Reported results 2009-012566-32 A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Me... 2011-02-11 due-trials
Reported results 2009-012943-41 A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo P... 2012-12-21 due-trials
Reported results 2009-013538-26 A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma 2010-12-13 due-trials
Reported results 2009-013539-39 A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis 2010-09-27 due-trials
Reported results 2009-015939-33 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Pr... 2013-05-20 due-trials
Completed, but no date, and reported results 2009-015989-62 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute... bad-data
Reported results 2009-016119-38 A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis. 2011-04-06 due-trials
Completed, but no date, and reported results Terminated 2009-016163-12 A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis. bad-data
Trial is partly outside EEC, and reported results 2009-016203-32 An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) 2017-01-12 bad-data
Reported results 2009-016522-14 A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Studio mul... 2017-09-22 due-trials
Reported results 2009-017946-30 A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary... 2017-04-19 due-trials
Trial is partly outside EEC, and reported results 2009-017999-25 An Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to < 6 Years with Chronic Kidney Disea... 2015-09-23 bad-data
Reported results 2010-018314-75 A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acu... 2019-01-07 due-trials
Trial is outside EEC, and reported results 2010-018426-39 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia (ITP) bad-data
Reported results 2010-019543-19 A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects wth Inadequately Controlled Asthma 2011-12-21 due-trials
Reported results 2010-019544-39 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease 2011-10-15 due-trials
Reported results 2010-019821-32 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fal... 2016-12-16 due-trials
Reported results 2010-019987-35 A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim. 2013-12-26 due-trials
Reported results 2010-020398-18 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas 2012-12-12 due-trials
Reported results 2010-020454-34 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma Studio multicent... 2019-03-29 due-trials
Completed, but no date, and reported results Terminated 2010-020881-53 A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease bad-data
Reported results 2010-021003-24 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfun... 2013-04-18 due-trials
Reported results 2010-021846-23 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer 2014-02-21 due-trials
Reported results 2010-022270-14 Estudio abierto de extensión de fase 2 con conatumumab . A Phase 2 Open Label Extension Study of Conatumumab. 2020-02-05 due-trials
Reported results 2010-022951-49 A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory ... 2016-11-08 due-trials
Trial is partly outside EEC, and reported results 2010-023150-37 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving D... 2014-02-14 bad-data
Reported results 2010-023978-39 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma... 2012-12-12 due-trials
Trial is partly outside EEC, and reported results 2010-024264-18 A Single-Arm Multicenter Phase II Study preceded by Dose Evalua-tion to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Pati... 2016-06-20 bad-data
Reported results 2010-024393-19 A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals 2017-06-29 due-trials
Reported results 2011-001111-31 A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer 2015-11-18 due-trials
Reported results 2011-001112-53 A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Prim... 2016-12-05 due-trials
Reported results 2011-001456-11 A Multicenter, International, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Assess the Efficacy and Safety of AMG 785 Treatment in Postmenopausal Women With Osteoporosis Est... 2016-12-28 due-trials
Reported results 2011-001527-20 TIMI 57 - A Double-Blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination with HMG-CoA Reductase Inhibitors in ... 2012-04-05 due-trials
Reported results 2011-001528-39 "A Double-blind, Radomized, Placebo-comtrolled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia" "Estudio mul... 2012-05-16 due-trials
Reported results 2011-001529-26 A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA R... 2012-05-08 due-trials
Reported results 2011-001544-30 A Randomized, Placebo and Ezetimibe Controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10 Year Framingham Risk Score of 10... 2012-03-02 due-trials
Reported results 2011-001915-29 A Multicenter Controlled Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of AMG 145 Estudio de extensión abierto (OLE) controlado y multicéntrico para evaluar la seguri... 2018-06-20 due-trials
Reported results 2011-002114-36 Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer. Protocollo con accesso `œin aperto` su denosumab nei pazienti con carcinoma in stadio avanzato. 2018-08-10 due-trials
Reported results Terminated 2011-002150-31 An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin alfa in Paediatric Subjects From Birth to Less than 1 Year of Age With Anem... 2021-05-20 due-trials
Reported results 2011-002257-61 An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) ... 2017-01-03 due-trials
Reported results 2011-003142-41 A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis 2018-02-28 due-trials
Reported results 2011-003827-37 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects 2013-10-14 due-trials
Trial is partly outside EEC, and reported results 2011-004618-40 An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years With Chronic Kidney Disease and S... 2016-06-04 bad-data
Reported results 2011-004844-23 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299) Studio di fase 2, randomizzato, in doppio cie... 2013-06-14 due-trials
Reported results Terminated 2011-004845-42 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165) 2013-05-20 due-trials
Reported results 2011-004923-11 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Ga... 2015-09-10 due-trials
Trial is partly outside EEC, and reported results 2011-005019-96 A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) 2019-08-15 bad-data
Reported results 2011-005251-13 A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis Studio rand... 2018-04-10 due-trials
Trial is partly outside EEC, and reported results 2011-005399-40 A two part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia Part A - Open-label, Single-arm, Multicenter Pilot Stu... 2014-01-31 bad-data
Reported results 2011-005400-15 A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia 2018-05-11 due-trials
Reported results 2011-005781-38 An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE) Blinatumomab in Patients with Relapsed/Refractory Diffuse Large B-Cell... 2015-09-09 due-trials
Reported results 2012-000307-32 A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melan... 2021-03-09 due-trials
Reported results 2012-000327-40 A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and ... 2015-08-19 due-trials
Reported results 2012-000529-31 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease 2018-04-10 due-trials
Reported results Terminated 2012-000651-13 A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1 2015-10-02 due-trials
Reported results 2012-000656-34 A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG... 2016-10-16 due-trials
Reported results 2012-000667-24 A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG... 2016-10-20 due-trials
Trial is outside EEC, and reported results 2012-001145-40 Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trials bad-data
Trial is outside EEC, and reported results 2012-001171-37 A Phase IV Registry of Etanercept in Children With Juvenile Rheumatoid Arthritis bad-data
Trial is outside EEC, and reported results 2012-001186-33 An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis bad-data
Reported results 2012-001362-15 A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Sc... 2013-10-29 due-trials
Reported results 2012-001363-70 A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With ... 2013-12-04 due-trials
Reported results 2012-001364-30 A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Re... 2013-11-19 due-trials
Reported results 2012-001365-32 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia 2013-12-19 due-trials
Reported results 2012-001382-32 A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects with Type 2 Diabetes Mellitus 2012-10-19 due-trials
Reported results 2012-001398-97 A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With... 2016-11-11 due-trials
Reported results 2012-001821-28 A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates 2015-01-07 due-trials
Reported results 2012-002805-23 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ... 2014-06-12 due-trials
Reported results 2012-002806-31 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ... 2014-05-09 due-trials
Reported results 2012-002808-41 A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialy... 2016-07-15 due-trials
Reported results 2012-002948-24 An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment with AMG 785 in Postmenopausal Women with Osteoporosis Previously Treated with Bisphosphonate Therapy 2015-05-15 due-trials
Reported results 2012-003351-11 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility 2015-05-01 due-trials
Reported results 2012-004208-37 A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of Evolocumab (AMG-145) Treatment on Atherosclerotic Disease Burden As Measured By Intravasc... 2016-07-29 due-trials
Reported results 2012-004319-29 A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer 2017-01-27 due-trials
Reported results 2012-004357-83 A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 2018-05-31 due-trials
Reported results 2012-005331-90 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention 2019-11-12 due-trials
Reported results 2013-000192-33 A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG ... 2014-12-24 due-trials
Reported results 2013-000434-35 A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Ost... 2015-01-08 due-trials
Reported results 2013-000525-31 A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis 2014-11-19 due-trials
Reported results 2013-000536-10 A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute ... 2017-03-14 due-trials
Reported results 2013-000537-12 A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis 2015-03-18 due-trials
Reported results 2013-000706-36 A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leu... 2017-01-06 due-trials
Reported results 2013-000723-14 A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or... 2017-12-06 due-trials
Completed, but no date, and reported results 2013-000727-13 Single arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome bad-data
Reported results 2013-000738-36 A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer 2015-07-23 due-trials
Reported results 2013-000935-29 A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-Co... 2017-11-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-001277-24 A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenoc... 2016-10-10 bad-data
Reported results 2013-001279-19 A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis 2015-07-09 due-trials
Reported results 2013-001662-42 A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer 2017-11-28 due-trials
Reported results 2013-001707-36 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention 2016-07-06 due-trials
Reported results 2013-003553-16 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-2 2015-10-01 due-trials
Reported results 2013-003554-25 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-1 2015-10-22 due-trials
Reported results 2013-004136-30 A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis 2017-09-28 due-trials
Reported results 2013-004654-13 An Open-Label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis 2016-04-11 due-trials
Trial is partly outside EEC, and reported results 2013-004958-18 A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis 2016-06-23 bad-data
Reported results 2013-005311-27 An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334 2017-06-26 due-trials
Reported results 2013-005542-11 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) 2019-06-28 due-trials
Exempt, with results 2013-005543-90 A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis 2018-10-08 not-yet-due
Reported results 2013-005551-32 A Multicenter, Randomized, Double blind, Placebo controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis 2016-04-20 due-trials
Reported results 2013-005552-15 A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Immunoprofile Intratumoral CD8+ Cell Density in Subjects With Unresected S... 2020-12-25 due-trials
Trial is partly outside EEC, and reported results 2014-000184-40 Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta Prospektivní, multicentrické, jednoramenné klinic... 2022-03-28 bad-data
Exempt, with results 2014-000185-22 A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma 2021-03-11 not-yet-due
Reported results 2014-001146-13 A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to... 2022-04-28 due-trials
Reported results 2014-001524-30 A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab 2018-03-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-001633-84 Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblasti... 2024-06-28 bad-data
Reported results 2014-001700-21 An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (A... 2020-01-10 due-trials
Reported results 2014-001976-75 A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Backgroun... 2016-11-11 due-trials
Reported results 2014-002108-25 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TR... 2020-07-17 due-trials
Trial is partly outside EEC, and reported results 2014-002277-11 Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Cholesterol... 2019-12-25 bad-data
Trial is partly outside EEC, and reported results 2014-002476-92 A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consol... 2022-12-05 bad-data
Completed, but no date, and reported results 2014-002834-30 A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma bad-data
Trial is partly outside EEC, and reported results 2014-003563-38 A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Di... 2017-03-15 bad-data
Reported results Terminated 2014-003701-15 A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis 2015-05-28 due-trials
Reported results 2014-004463-20 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention 2017-03-20 due-trials
Reported results 2014-004464-38 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention 2017-06-19 due-trials
Reported results 2014-004704-29 A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis 2018-08-13 due-trials
Reported results 2014-004868-38 A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis. 2019-12-06 due-trials
Reported results 2014-004869-24 A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis. 2018-07-06 due-trials
Trial is outside EEC, and reported results 2014-005034-66 An Open-label, Randomized, Single-dose, 3-period, 3-treatment Crossover Study to Assess the Comparative Bioavailability of 5mg Cinacalcet Capsules to the 30mg Commercial Formulation Cinacalcet Tablets... bad-data
Trial is outside EEC, and reported results 2014-005190-36 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors bad-data
Exempt, with results 2014-005386-67 A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and t... 2023-07-11 not-yet-due
Reported results 2015-001343-37 A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evoloc... 2017-01-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-002276-25 Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From ... 2021-06-01 bad-data
Reported results 2015-002322-40 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina 2017-04-13 due-trials
Trial is outside EEC, and reported results 2015-002466-22 A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open­label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-met... bad-data
Exempt, with results 2015-003011-38 A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in combination with Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head ... 2020-08-28 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-003196-29 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials 2021-09-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2015-003645-25 A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous SystemTumors That ... 2022-11-29 bad-data
Reported results 2015-003731-35 A Randomized Double-blind Placebo Controlled Study Characterizing The Effects of PCSK9 Inhibition On Arterial Wall inflammation in Patients With Elevated Lp(a) 2018-04-05 due-trials
Reported results 2015-004711-21 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercho... 2017-09-05 due-trials
Reported results 2015-004735-12 A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mi... 2020-01-27 due-trials
Reported results 2015-004780-36 A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease 2022-03-24 due-trials
Trial is partly outside EEC, and reported results 2015-005051-28 An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Second... 2018-10-29 bad-data
Exempt, with results 2016-001080-36 A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors 2019-05-17 not-yet-due
Reported results 2016-002044-16 A Phase 2/3 Multi-center Study of Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma 2020-03-12 due-trials
Reported results 2016-002190-35 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL) 2019-10-28 due-trials
Reported results 2016-002299-28 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced... 2020-09-14 due-trials
Trial is partly outside EEC, and reported results 2016-003083-39 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis 2023-12-14 bad-data
Reported results 2016-003255-30 A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transpla... 2019-09-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-003554-33 A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Myelom... 2022-04-15 bad-data
Listed as ongoing, but also has a completion date and reported results 2016-004066-26 A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries 2022-03-04 bad-data
Reported results 2017-000630-57 A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention. 2019-02-04 due-trials
Reported results Terminated 2017-000675-90 A Phase 3b, Multicenter, Randomized, Double-blind, Parallel Group, Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate Se... 2017-05-29 due-trials
Exempt, with results 2017-000763-33 A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versus H... 2022-10-13 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2017-001418-27 A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) 2022-07-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-001758-32 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Follow-up sulla sicurezza a lungo termine dei pazienti con tumore a cellule giganti del... 2023-07-27 bad-data
Exempt, with results 2017-001944-36 A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy 2020-05-13 not-yet-due
Exempt, with results 2017-001997-41 A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide, with and without Dexamet... 2023-06-30 not-yet-due
Ongoing 2017-002397-39 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Epis... not-yet-due
Ongoing 2017-002399-23 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chro... not-yet-due
Trial is outside EEC 2017-002411-34 Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to < 18 Years of age With Second... bad-data
Trial is outside EEC, and reported results 2017-002659-28 An open-label, Randomized, Single-dose, 2-Period, "-Treatment Crossover Study to Assess the Bioequivalence of Cinacalcet Capsule (Administered as Six of the 5 mg Cinacalcet Capsules) with 30 mg Commer... bad-data
Ongoing 2017-002992-25 A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Ga... not-yet-due
Reported results 2017-003236-37 High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS) 2021-01-21 due-trials
Reported results 2017-003512-40 A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthc... 2020-01-08 due-trials
Trial is outside EEC, and reported results 2017-003778-15 A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study) bad-data
Reported results 2017-004972-74 An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta 2023-03-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-000550-21 Multicenter, Single-arm Open-label Extension Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta 2022-03-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-000665-36 A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A... 2023-03-31 bad-data
Trial is outside EEC 2018-000923-15 A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine bad-data
Ongoing 2018-001006-28 PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-s... not-yet-due
Reported results 2018-001233-40 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decr... 2021-11-29 due-trials
Exempt 2018-001400-11 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutat... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-001997-52 A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis. 2020-12-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-002608-15 A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis 2022-02-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-002735-26 A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ... 2023-07-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-002748-10 A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis 2022-05-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-002850-58 A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PS... 2021-11-04 bad-data
Exempt, with results 2018-002879-17 A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma 2022-04-21 not-yet-due
Reported results 2018-002918-12 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderat... 2023-03-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-003342-16 A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache Studi... 2023-06-13 bad-data
Other 2018-004565-14 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial I... not-yet-due
Ongoing 2018-004608-21 Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents > = 2 to < 18 Years of age With Secondary Hyperpa... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-000328-16 A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy 2023-07-25 bad-data
Listed as ongoing, but also has a completion date 2019-001169-34 An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd) 2024-10-01 bad-data
Reported results 2019-001575-37 Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311 2020-09-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-001906-61 Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy 2024-02-26 bad-data
Reported results 2019-002331-28 Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE) 2023-01-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-002503-17 A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration 2023-01-30 bad-data
Other 2019-002787-27 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 t... not-yet-due
Other 2019-002788-88 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years ... not-yet-due
Other 2019-003497-13 A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis not-yet-due
Ongoing 2019-003582-18 A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjec... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-003646-33 Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase... 2023-10-26 bad-data
Reported results 2019-003688-23 A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lip... 2022-11-08 due-trials
Exempt 2019-004780-52 A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Pre... not-yet-due
Exempt, with results 2020-001305-23 A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) 2023-10-23 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-002759-39 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria 2023-04-13 bad-data
Reported results Terminated 2020-003057-30 Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF 2020-12-10 due-trials
Reported results 2020-003184-25 A Phase 3, Multicenter , Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis 2022-06-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2020-003509-72 A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy 2023-05-22 bad-data
Listed as ongoing, but also has a completion date 2020-004498-29 Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Ac... 2023-11-03 bad-data
Exempt 2020-004721-23 A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101) not-yet-due
Trial is outside EEC, and reported results 2020-005111-51 A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients with Homozygous Familial Hypercholesterolemia (HoFH) in India bad-data
Reported results 2020-005205-42 A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in ... 2023-02-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2020-005279-11 A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotorasib) for the Treatment of Subjects in Selected European Countries with Previously Treated Locally Advanced and Unr... 2022-08-11 bad-data
Reported results 2021-000542-18 A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With Con... 2022-12-19 due-trials
Other 2021-002537-41 A Phase 2, Dose-Finding, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severe... not-yet-due
Ongoing 2021-002566-40 A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment not-yet-due
Listed as ongoing, but also has a completion date 2021-002638-18 A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment 2022-11-07 bad-data
Other 2021-003461-35 A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or... not-yet-due
Other 2021-003477-61 A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer ... not-yet-due
Other 2021-004008-16 A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previ... not-yet-due
Other 2021-005272-19 EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction not-yet-due
Exempt 2021-006386-38 A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE 301) not-yet-due
Ongoing 2022-001257-22 Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Non Asian Adult Severe Aplastic Anemia (SAA) Subjects who are Either Previously Untreated With Immunosuppressive Ther... not-yet-due
Other 2022-001686-12 A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis not-yet-due
Other 2022-002470-86 A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Ty... not-yet-due
Other 2022-003024-41 A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juveni... not-yet-due